Familial Gynaecological Cancers

Slides:



Advertisements
Similar presentations
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Advertisements

AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
Computer Solutions to Identify and Manage Women at High Risk
Benefits and Risks of GnRH/LHRH Agonists and Antagonists in Advanced Prostate Cancer Patients John Trachtenberg, MD Director, Prostate Cancer Princess.
Breast Cancer Patient Issues in Family Practice: An Interactive Session.
Minimally Invasive Surgery in Gynecologic Oncology
Menopause in Women With IBD. Menopause Natural menopause results from gradual decline in number of estradiol-producing ovarian follicles Natural menopause.
Addition and Subtraction Equations
Breast Cancer Risk Assessment and Genetic Testing
CALENDAR.
The Relationship between Childbearing and Transitions from Marriage and Cohabitation in Britain Fiona Steele 1, Constantinos Kallis 2, Harvey Goldstein.
The basics for simulations
MENOPAUSAL HORMONAL TREATMENT AND BREAST CANCER RISK PROF DR H DEPYPERE Gynaecologische oncologie en borstkliniek, Universitair Ziekenhuis, Gent.
Re-testing for Chlamydia trachomatis Infection in Massachusetts Family Planning Clinics Marie E. Caggiano, William G. Dumas, Thomas E. Bertrand, Katherine.
1 Epidemiology and clinical relevance. 2 World (thousands) cases: 204 Deaths 125 Europe cases: 63 Deaths 40.
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Recent advances in Radiotherapy of CNS Tumours Dr Vivek Bansal Director, Dept of Radiation Oncology HCG Cancer Centre,Sola Ahmedabad,Gujarat,India .
Hereditary GI Cancer-a Primer for Medical Oncologists
PSA: Fact or Fiction The debate as it stands
Hereditary GI Cancer Syndromes: Keys to identify high risk patients
Before Between After.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Genomics-Based Personalized Healthcare Presented by: Charis Eng, MD, PhD -Chair & Director -Genomic Medicine Institute -Director -Center for Personalized.
Static Equilibrium; Elasticity and Fracture
CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.
Current Issues in Hereditary Breast Cancer
Biostatistics course Part 14 Analysis of binary paired data
Women’s Health Initiative - Summary of results DISCLAIMER Menopausetoday gives the following presentation for your information and.
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
Gynecologic Cancers Presented by: Michael Goodheart, MD Assistant Professor Gynecologic Oncology The University of Iowa Hospitals & Clinics Understanding,
Hereditary Factors in Breast Cancer
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
Genetics and Ovarian Cancer Jeanne M. Schilder, M.D. Associate Professor, Gynecologic Oncology Indiana University Medical Center September 19, 2012.
Breast Cancer Risk and Risk Assessment Models
Morning Report May 20, 2009 Bridger Clarke  Born in Lawrence, Massachusetts, on 4 January  Dropped out of high school at the age of fourteen.
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
Max Brinsmead MB BS PhD May 2015
Materials & Methods Prospective study in tertiary oncology centre. PJ used in 15 laparotomies and 6 laparoscopic debulking. Patient demographics, intra.
Ovarian cancer….. in 15 minutes
Genetics and Risk of Breast Cancer What is the Evidence.
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Genetics & Colorectal Cancer
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
SUMAYYA EBRAHIM GYNAECOLOGIST PARKLANE CLINIC JOHANNESBURG
Familial Ovarian Cancer Diane Stirling. Ovarian cancer in the UK 5th highest incidence of ovarian cancer. 4th most common cancer in women Risk of developing.
Prevention of Ovarian Cancer Roberta B. NessRoberta B. Ness, M.D., M.P.H., Chair of the Department of Epidemiology, University of Pittsburgh, Graduate.
Dr Matt Hewitt Prophylactic Bilateral Salpingoophorectomy.
Cancer Risk Assessment Judith A Westman MD Clinical Director Division of Human Genetics.
Hysterectomy for Undergraduates
Clinical Utility of BRCA Testing Mark Robson, MD September 7,
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
Summer Dewdney, MD Rush University Medical Center.
Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.
Gynecological Malignancies. Gynecologic malignancies account for 15% of all cancers in women. Gynecologic malignancies account for 15% of all cancers.
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Volume 32, Number 19, July. 1, 2014, from J Clin Oncol Chen.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Identifying and Managing Hereditary Cancer Syndromes © 2005 Myriad Genetic Laboratories, Inc. Monica Trout, MS Genetic Counselor / Regional Medical Specialist.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.
Breast Cancer Risk Assessment & Prevention Strategies Generosa Grana, MD Professor, Cooper Medical School of Rowan University Director, MD Anderson Cancer.
Screening for Ovarian Cancer
Surgical Management of the Breast in Breast Cancer
Ovarian Cancer: The Last 20 Years – The Next 20 Years
Ovarian Cancer Facts and Figures
MAINTENANCE THERAPY WITH PARP INHIBITORS
Prophylactic Oophorectomy
Presentation transcript:

Familial Gynaecological Cancers A/Prof Andreas Obermair Gynaecological Oncologist RBWH, Greenslopes Private Hospital www.obermair.info

Major Known Mutations BRCA1 BRCA2 Mismatch Repair Genes Other undiscovered

Hereditary Ovarian Cancer BRCA1 life-time risk 16-54% BRCA2 life-time risk 10-25% Risks vary depending on the population being studied ~10% of cancer due to these genes ? Primary Peritoneal Cancer, Fallopian Tube Cancer

HNPCC(Lynch Syndrome Type II) Microsatillite DNA sequences which are prone to mutation during replication HNPCC & endometrial cancer Rare: Urological tumours MSH2 & MLH1 genes most commonly implicated

HPNCC/mismatch repair genes Most have colon cancer penetrance of 30-70% Endometrial Ca 42% Annual Uterine sampling &Transvaginal Ultrasound Hysterectomy at time of colectomy

Cancer Gene Testing in Qld Qld Clinical Genetics Service established in 1995 Funding for 50 tests per year Uses software to estimate individuals with a risk >15% May not detect all predisposing mutations Requires a blood sample from an affected living relative

Hereditary Ovarian Cancer 4 Cohort studies (2 retrospective, 2 prospective) 1 family history only, 3 BRCA mutations All 4 studies found protective effect of surgery Variability in patient populations & patient methodology

BSO group – 6 cases of stage 1 ovarian ca Rebbeck et al. The Prevention and Observation of Surgical end points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N.Eng.J.Med. 346(2002),pp.1616-1622 Retrospective cohort of 259 women with BSO and 292 no BSO (matched control group) BSO group – 6 cases of stage 1 ovarian ca 2 cases of peritoneal ca found 3.8&8.6 yrs later No BSO –58 ovarian ca (8.8yrs median follow-up) Only 6 stage 1(11%)

98 BSO vs. 72 who chose not to have BSO Kauff et al. Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N.Eng.J.Med.346(2002),pp 1609-1615 Prospective 98 BSO vs. 72 who chose not to have BSO 2 groups similar age & other risk factors Mean follow-up 25.4 months BSO – 1 peritoneal Ca (16.3 months) No BSO –4 ovarian Ca 8 breast Ca, 1 peritoneal Ca

All patients had prophylactic BSO 6 women primary peritoneal Ca (1.9%) Piver et al. Familial Ovarian Cancer.A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71(1993) pp582-588 324 women (familial ovarian cancer registry) with family history of 2 or more 1st or 2nd degree relatives with ovarian Ca All patients had prophylactic BSO 6 women primary peritoneal Ca (1.9%) Residual risk of Primary Peritoneal Cancer

Summary Prophylactic Surgery Risk of ovarian cancer reduced by > 95% Most patients found at stage 1 (prognosis  ) Risk of breast cancer reduced by 50% Risk of occult cancer found at surgery 14 to 18% Residual risk of primary peritoneal cancer < 2%

Risks of surgery Risks of laparotomy ~ 17% Risks of laparoscopy ~ 4%

274 pts (141 co-existent gynae problems) Elit et al . Prophylactic oophorectomy in Ontario. Fam. Cancer 1 (2001),pp. 143-148 Ontario Hospital based study 41 institutions prophylactic BSO from 1992-1998 274 pts (141 co-existent gynae problems) 15.7% complications –bleeding, infection, damage to organs - most laparotomy

1 re-operation for small bowel obstruction Krauf et al. Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. N.Eng.J.Med.346(2002),pp. 1609-1615 98 BSO - complications 4 1 re-operation for small bowel obstruction Increasing trend to laparoscopy with risk of complications 0.22-4.0%

Long-term adverse effects Menopause lipid profile 2x CAD Osteoporosis Higher rate of decreased libido & sexual satisfaction Role of HRT

Surgical Options Minimum of BSO Peritoneal lavage for cytology Occult ovarian or fallopian tube Ca Fallopian tube and Infundibulo-Pelvic Ligament need to be removed completely. Age? Uncommon in women < 35 years Peritoneal lavage for cytology 35 women, 3 + cytology 1occult fallopian tube Ca, 1 fallopian ACIS 1 no histological evidence of Ca Coglan et al. Gynecol Oncol. 85(2002), pp.397-403

Role of Hysterectomy ? Increased risk of endometrial Ca Hysterectomy guarantees complete resection of fallopian tube HRT simplified But increased morbidity

Benefits on Breast Cancer Prophylactic BSO protective for breast Ca RR 0.47(95% CI 0.29-0.77) HRT did not negate the reduction in breast Ca Rebbeck et al Natl. Cancer Inst. 91(1999) pp1475-1479 Proportion Breast Ca free at 5 yr 94% BSO group 79% surveillance group(p=0.07) Kauff et al N.Engl.J.Med. 346(2002),pp 1609-1615

Alternative to oophorectomy Oral contraceptives - Controversies 60% reduction in Ovarian Cancer if used for >6yrs Narod et al. N.Engl.J.Med.339(1998) No reduction in study in Israel But small study & wide confidence limits Modan et al. N.Eng.J.Med. 345(2001)

Tubal Ligation Associated with decreased incidence in general population (?reason) BRCA1 Tubal ligation in 232 assoc with odds ratio of 0.39 (95% confidence limits 0.22-0.70) Tubal ligation & OCP 0.28 (95% confidence limits 0.15-0.52) Narod et al. Lancet. 357(2001)pp.1467-1470

Perceptions of women with BRCA1/2 Mutations Psychological testing on those with surgery vs. observation, Anxiety reduced with surgery, 86% high level of satisfaction. Tiller et al.: Gynecol Oncol 2002

Discussion No randomized control trials of surgery vs. observation Cohorts studies showed risk reduction Complications are low (note impact of laparoscopic surgery) Optimal procedure is not well defined Fallopian tube ca Role OCP & tubal ligation

Conclusions Women with family history should be assessed for genetic counseling & possible testing Surgery - ovary + fall. tube MUST BE removed Young women (< 35 years) >> ?role of OCP+/- tubal ligation

www.obermair.info 07 3830 5824